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Folic acid improves renal function  
— in what mechanism?
Kwas foliowy poprawia czynność nerek — w jakim mechanizmie?
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In their interesting study published recently in “Kardiologia 
Polska” Mierzecki et al. [1] aimed to evaluate the effect of a diet 
containing low vs. moderate amounts of folic acid (FA) on sev-
eral parameters of inflammation and blood coagulation, lipid 
profile, and renal function in apparently healthy young patients 
with risk factors for atherosclerosis. Additional administration 
of 0.4 mg/d FA reduced plasma concentrations of total homo-
cysteine (tHcy) by about 20%, in line with increased serum FA 
levels, regardless of the self-reported dietary intake of FA [1]. 
A higher intake of FA did not have a significant impact on any 
of the variables measured except for a 22.5% decrease in serum 
creatinine and 9.9% increase in estimated glomerular filtration 
rate (eGFR) in young subjects who reported FA intake below 40% 
of the reference value. To reinforce the concept of FA supple-
mentation as a factor improving renal function, it would be of 
interest to assess associations between FA-induced changes in 
renal function and alterations in tHcy and FA concentrations. It 
is known that FA supplementation improves endothelial function 
via multiple mechanisms, and its noninvasive assessment (e.g. 
using tonometry) could validate this hypothesis [2], possibly 
confirming that this mechanism is important in increasing GFR 
observed in young people following FA. Moreover, given the 
key role of the kidneys in clearance of Hcy, the study results 
suggest that lowering Hcy, not increasing FA concentration, may 
be a ‘primary’ event that leads to improvement in renal function. 
Even more interestingly, although the baseline renal function, 
as well as tHcy, in the study subjects were normal, there was 
still the potential to increase GFR following intake of FA. It is 
unclear, however, whether improved renal function following FA 
administration can also be observed in older patients suffering 
from cardiovascular disease, in whom endothelial dysfunction 
is common, and if this effect can be beneficial in terms of major 
clinical outcomes, or neutral, as indicated by several clinical 
trials cited in the paper [1].
An additional effect of hyperhomocysteinaemia associated 
with cardiovascular risk and modulated by FA is post-trans-
lational protein Ne-homocysteinylation, which may trigger 
autoimmune response and lead to the formation of potentially 
harmful specific antibodies, as shown in patients with early-onset 
coronary artery disease or renal insufficiency [3, 4]. Antibodies 
to Ne-homocysteinylated proteins may bind to them, with 
immune complex formation within the glomeruli and tubules; 
it is possible that lowering tHcy with FA may limit renal injury 
through mitigation of antibody formation. However, it seems 
unlikely that FA supplementation in a relatively short period 
of time would be sufficient to lower autoantibodies against 
Ne-homocysteinylated proteins, despite a marked decrease 
in tHcy (as demonstrated in 2006) [5]. It is worth investigating 
whether improved renal function in young individuals following 
a three-month FA administration can affect Ne-homocysteinyla-
tion and its potential consequences. Recently, elevated Hcy has 
been shown to specifically up-regulate the inflammatory process 
and oxidative stress that lead to podocyte injury in an animal 
model [6]. It could be speculated that attenuation of this mecha-
nism contributes to increased GFR during FA administration, as 
reported by Mierzecki et al. [1]. Elucidation of the phenomenon 
of FA-induced improvement of renal function among healthy 
people is an attractive area of further research. 
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